Lomibuvir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lomibuvir (VX-222) 是一种选择性的非核苷聚合酶抑制剂，靶向丙型肝炎病毒 NS5B 聚合酶 (RdRp) 的拇指口袋 2，Kd 为 17 nM。Lomibuvir 抑制 1b/Con1 型 HCV 亚基因组复制子，EC50 为 5.2 nM。Lomibuvir 优先抑制延长的 RNA 合成，而非从头合成的 RNA。

Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis.

Lomibuvir (VX-222) inhibits WT HCV 1b/Con1 replicon with an EC50 of 5.2 nM. Lomibuvir inhibits M423T, L419M and I482L (mutant replicons) with EC50s of 79.8, 563.1, 45.3 nM, respectively. Lomibuvir reduces de novo initiation slightly but also shows strong inhibition of primer extension. The IC50 of Lomibuvir for primer-extended RNA synthesis is 31 nM.Lomibuvir is a non-nucleoside, allosteric inhibitor of the hepatitis C virus NS5B polymerase.

——

——

Others

Other Targets

HCV Protease

——

——

1026785-55-6

445.61

C25H35NO4S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (224.41 mM; 超声助溶 )

CC1CCC(CC1)C(=O)N(C1CCC(O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years